Equibles does not estimate personal net worth.
John Nicols was last confirmed as Board Member at Codexis, Inc. (CDXS) in a filing dated April 27, 2023. Earlier roles on record: CEO at Codexis, Inc. (CDXS) until August 8, 2022. Codexis, Inc. reported in an 8-K filed July 18, 2022 that John Nicols retired as President and Chief Executive Officer, effective August 8, 2022. The proxy statement of Codexis, Inc. reports total compensation of $3,438,179 for John Nicols in fiscal 2021, including a base salary of $696,562. Disclosed compensation is on record for 5 fiscal years. John Nicols has spoken on 10 earnings calls across 1 company, most recently for Codexis, Inc. on August 4, 2022. The companies whose calls John Nicols spoke on are classified in the Healthcare sector.
“Dr. Dilly succeeds John Nicols, the Company's current President and Chief Executive Officer, who notified the Board of his intention to retire from such roles effective August 8, 2022.”
“First, it's great to spend this time with all of you today. Those who have been following us for a while know that for the last five-plus years, we have been on a very strong, sustained growth trajectory with a remarkable track record of financial and strategic execution.”
“I'm pleased to report that Codexis has delivered another very strong quarter of top-line growth as we kick off 2022. Total revenue of $35.3 million for the first quarter of 2022 nearly doubled year-over-year.”
“We are very pleased to report exceptional fiscal year 2021 results for Codexis and to discuss the exciting growth drivers that will continue to accelerate company momentum through 2022 and beyond.”
“I am proud to report that Codexis has delivered another quarter of exceptional operational performance. Total revenue for the third quarter of 2021 grew 100% year-over-year.”
“I am very pleased to report exceptionally strong second quarter 2021 results for Codexis. Total revenue for the quarter grew by an impressive 70% year-over-year.”
Start not stated–2023-04-27
Last confirmed by a filing; no departure on record
Start not stated–2022-08-08
CDXS
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Codexis, Inc. (CDXS) | Former President and Chief Executive Officer | $696,562 | $3,438,179 |
| 2020 | Codexis, Inc. (CDXS) | Former President and Chief Executive Officer | $686,667 | $2,960,857 |
| 2019 | Codexis, Inc. (CDXS) | President and Chief Executive Officer | $628,014 | $3,408,034 |
| 2018 | Codexis, Inc. (CDXS) | President and Chief Executive Officer | $646,833 | $3,438,812 |
| 2017 | Codexis, Inc. (CDXS) | President and Chief Executive Officer | $627,500 | $2,942,516 |
